ES2652643T3 - Péptidos terapéuticos y su uso contra la corea de Huntington - Google Patents
Péptidos terapéuticos y su uso contra la corea de Huntington Download PDFInfo
- Publication number
- ES2652643T3 ES2652643T3 ES12722415.2T ES12722415T ES2652643T3 ES 2652643 T3 ES2652643 T3 ES 2652643T3 ES 12722415 T ES12722415 T ES 12722415T ES 2652643 T3 ES2652643 T3 ES 2652643T3
- Authority
- ES
- Spain
- Prior art keywords
- chorea
- use against
- therapeutic peptides
- sequence seq
- against huntington
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K4/00—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
- C07K4/12—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
- C07K2319/41—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a Myc-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Péptido aislado que consiste en la secuencia SEQ ID NO: 5, o fragmento del mismo que presenta un tamaño inferior a 100 aminoácidos y que comprende la secuencia SEQ ID NO: 4, o cualquier péptido o fragmento que presenta al menos el 80% de identidad con la secuencia SEQ ID NO: 4, y que tiene un efecto protector sobre la agregación de las proteínas poliQ-hHtt.
Description
Claims (1)
-
imagen1
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1153193 | 2011-04-12 | ||
FR1153193 | 2011-04-12 | ||
PCT/FR2012/050809 WO2012140376A1 (fr) | 2011-04-12 | 2012-04-12 | Peptides therapeutiques et leur utilisation contre la choree de huntington |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2652643T3 true ES2652643T3 (es) | 2018-02-05 |
Family
ID=46146914
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES12722415.2T Active ES2652643T3 (es) | 2011-04-12 | 2012-04-12 | Péptidos terapéuticos y su uso contra la corea de Huntington |
Country Status (6)
Country | Link |
---|---|
US (1) | US8987211B2 (es) |
EP (1) | EP2697253B1 (es) |
AU (1) | AU2012241648B2 (es) |
CA (1) | CA2832521C (es) |
ES (1) | ES2652643T3 (es) |
WO (1) | WO2012140376A1 (es) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010138919A2 (en) | 2009-05-28 | 2010-12-02 | Angiodynamics, Inc. | System and method for synchronizing energy delivery to the cardiac rhythm |
US9895189B2 (en) | 2009-06-19 | 2018-02-20 | Angiodynamics, Inc. | Methods of sterilization and treating infection using irreversible electroporation |
US9700368B2 (en) | 2010-10-13 | 2017-07-11 | Angiodynamics, Inc. | System and method for electrically ablating tissue of a patient |
JP2017523165A (ja) * | 2014-07-10 | 2017-08-17 | アフィリス・アクチェンゲゼルシャフトAffiris Ag | ハンチントン病の予防および/または処置における使用のための薬剤および方法 |
NZ728041A (en) * | 2014-07-10 | 2023-01-27 | Affiris Ag | Substances and methods for the use in prevention and/or treatment in huntington’s disease |
US11639371B2 (en) * | 2016-02-17 | 2023-05-02 | The Chinese University Of Hong Kong | Peptidylic inhibitors of nucleolin (NCL) targeting CAG-repeat RNA toxicity and methods for reducing polyQ-mediated toxicity in polyQ diseases |
US10905492B2 (en) | 2016-11-17 | 2021-02-02 | Angiodynamics, Inc. | Techniques for irreversible electroporation using a single-pole tine-style internal device communicating with an external surface electrode |
CN111393509B (zh) * | 2020-03-30 | 2022-03-29 | 国家纳米科学中心 | 靶向特异性多肽及其应用 |
US20230322854A1 (en) * | 2020-09-03 | 2023-10-12 | University Of Southern California | Huntingtin-related peptide agents and uses thereof |
WO2023152669A1 (en) * | 2022-02-11 | 2023-08-17 | Università Degli Studi Di Padova | Therapeutic factors for the treatment of polyq diseases |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6632616B2 (en) | 2000-03-16 | 2003-10-14 | Duke University | Compounds that selectively bind to expanded polyglutamine repeat domains and methods of use thereof |
WO2004103159A2 (en) * | 2003-05-14 | 2004-12-02 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for modulating endometrium |
US8153760B2 (en) * | 2005-01-19 | 2012-04-10 | Donald Danforth Plant Science Center | Rhinovirus vaccines |
US8518942B2 (en) | 2008-08-06 | 2013-08-27 | Buck Institute For Research On Aging | Caspase inhibitors and uses thereof |
-
2012
- 2012-04-12 AU AU2012241648A patent/AU2012241648B2/en active Active
- 2012-04-12 CA CA2832521A patent/CA2832521C/fr active Active
- 2012-04-12 EP EP12722415.2A patent/EP2697253B1/fr active Active
- 2012-04-12 US US14/111,285 patent/US8987211B2/en active Active
- 2012-04-12 ES ES12722415.2T patent/ES2652643T3/es active Active
- 2012-04-12 WO PCT/FR2012/050809 patent/WO2012140376A1/fr active Application Filing
Also Published As
Publication number | Publication date |
---|---|
EP2697253A1 (fr) | 2014-02-19 |
CA2832521A1 (fr) | 2012-10-18 |
EP2697253B1 (fr) | 2017-09-20 |
AU2012241648A1 (en) | 2013-10-31 |
AU2012241648B2 (en) | 2016-11-17 |
WO2012140376A1 (fr) | 2012-10-18 |
US20140121167A1 (en) | 2014-05-01 |
CA2832521C (fr) | 2019-10-15 |
US8987211B2 (en) | 2015-03-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2652643T3 (es) | Péptidos terapéuticos y su uso contra la corea de Huntington | |
ES2512141T3 (es) | Análogo peptídico de oxintomodulina | |
ES2486675T3 (es) | Análogo de péptido de oxintomodulina | |
ES2619322T3 (es) | Agente inductor de inmunidad | |
HRP20191254T1 (hr) | Peptidi koji prodiru u stanice i postupci za njihovu proizvodnju i uporabu | |
TN2017000085A1 (en) | Polypeptide having a polyester degrading activity and uses thereof | |
ES2691070T3 (es) | Péptidos antiinflamatorios y composición que comprende los mismos | |
ES2586418T3 (es) | Vacuna de proteína de fusión | |
ES2534752T3 (es) | Nuevo péptido antigénico contra el cáncer y utilización del mismo | |
EP3363458A3 (en) | A peptide | |
UA118167C2 (uk) | Пептид та його застосування | |
WO2014139476A8 (zh) | Rsv融合蛋白的表位以及识别其的抗体 | |
MX2016002937A (es) | Vacuna oncologica. | |
PE20140617A1 (es) | Alfa glucosidasa acida modificada con procesamiento acelerado | |
AR120721A2 (es) | Péptidos y composiciones para el tratamiento de daño articular | |
MX2013007872A (es) | Proteina de fusion anticancer. | |
AR067980A1 (es) | Peptidos de cdh3 y agentes que los comprenden | |
IN2014CH00391A (es) | ||
ECSP17044282A (es) | Formulación de relación fija de insulina glargina/lixisenatida | |
CY1121083T1 (el) | Αντιμικροβιακο πεπτιδιο και οι χρησεις αυτου | |
EP3360895A3 (en) | Preparation comprising factor viii and von willebrand factor peptides | |
ES2609817T3 (es) | Leucotoxina E/D como nuevo agente antiinflamatorio y microbicida | |
ES2666001T3 (es) | Variantes de proteasa mejoradas en cuanto al rendimiento | |
WO2018136803A8 (en) | Apoc-ii mimetic peptides | |
ES2536238T3 (es) | Péptidos antimicrobianos |